| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97ddd4d1d0ebc8a7d2c8e7d214d08cf3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 |
| filingDate |
2001-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44cdb85f8a3483e31819fba7d3008c76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_687ffcbe00c0825d023aae6081bf5b9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63d8a5dcda2d4a00f1cb3fda59a20397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64d457ef10b3728c33ac24996c0e5e92 |
| publicationDate |
2002-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1192950-A1 |
| titleOfInvention |
Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient |
| abstract |
A medicament safe and free from side effects, fornthe prevention or treatment of dermatitis exhibiting anbiphasic inflammation reaction or dermatitis induced bynrepeated exposure to an antigen, which suppresses thenprogress of the condition and improves the quality ofnlife of the patient, which medicament treats dermatitisnexhibiting a biphasic inflammation reaction or dermatitisninduced by repeated exposure to an antigen by including anquiazoline derivative having the formula (I) or (II) ornits pharmaceutically acceptable salt as an effectiveningredient: |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1876244-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8071307-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1876244-A1 |
| priorityDate |
2000-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |